Deejay78 OP : GEAR’s recent 1H2020 financial performances.
GEAR delivered a strong 1H2020 performance despite challenging economic conditions and being in the weakest coal price environment since 2015/2016.
• Production and sales volume for 1H2020 were 16.5 million tonnes (up 31.7% YoY) and 17.1 million tonnes (up 27.4% YoY) respectively.
• Strict controls on production cost ensured continued profitability despite low coal prices, with average cash cost at US$22.53 per tonne in 1H2020 (declined 4.4% YoY).
• The Group saw a surge in consolidated net profit to US$35.0 million (up 40.5% YoY), on the back of an 18.6% increase in revenue to US$593.5 million

Deejay78 OP : Golden Energy and Resources posts 18.7% drop in FY2020 earnings after acquisitions
Earnings per share for the full year fell to 0.34 US cent from 0.42 cent in FY2019.
In its results filing, Gear noted that its revenue grew 4.2 per cent to a record US$1.16 billion compared to US$1.12 billion in the year-ago period due to higher contributions from its metallurgical coal segment from the consolidation of Stanmore Coal.
The growth was partially offset by a decrease in revenue from the energy coal and non-coal businesses segments, which fell 4.5 per cent and 20.1 per cent respectively, due to lower coal average selling prices and the absence of consultancy services rendered.
Post the consolidation of Stanmore's results as well as higher barging and trucking expenses which came on the back of higher sales volumes, selling and distribution expenses for FY2020 grew 8.6 per cent to US$201.4 million, from US$185.4 million previously.
Administrative expenses increased 7.1 per cent to US$79.3 million from the year before, due to the consolidation of Stanmore's financial results.
The group also booked a US$4.9 million loss of a joint venture (net of tax) over the period due to its investment in the Ravenswood Gold project.
Gear's cash and cash equivalents stood at US$262.8 million as at Dec 31, 2020.

Deejay78 OP : Narrowing 1M Bollinger Band, MACD Bulish, RSI oversold, DMA up... waiting for take off

Deejay78 OP : Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The company’s Specialty Pharma Principals segment sells and markets specialty pharmaceutical products, including Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup, Lidose, and Piascledine through distributorship or licensing, and supply agreements. This segment offers products in various therapeutic areas or medical specialties, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology consist of ear, nose, and throat, orthopedic and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, and family medicine. Its Proprietary Brands segment develops, markets, and sells its own proprietary range of dermatological products and health supplement products. It offers dermocosmetic products under the Ceradan and TDF brands through medical professionals, including general practitioners, dermatologists, pediatricians, and pharmacists; and health supplement products under the Ocean Health brand directly to consumers via retail channels. The company’s Medical Hypermart and Digital segment engages in the wholesale of pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. This segment also operates an online B2B platform. It also markets and distributes its products in Hong Kong, Myanmar, Brunei, Bangladesh, Cambodia, and Oman. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore. Hyphens Pharma International Limited is a subsidiary of Inomed Holding Pte Ltd.

Deejay78 OP : STAY ABOVE 1W MID-BOLINGER BAND (0.323) AND ABOVE MA20 TO TOWARD ADVANCE